JW Pharmaceutical
Clinical trials sponsored by JW Pharmaceutical, explained in plain language.
A South Korean pharmaceutical company developing and marketing a range of medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo pill aims to tackle cholesterol in metabolic syndrome patients Results expected Dec 2026 (estimated)
- New skin cream tested on healthy people – no cure expected Results expected Dec 2026 (estimated)
- New combo pill showdown: which diabetes cocktail wins? Results expected Mar 2027 (estimated)
-
New combo pill aims to tackle cholesterol in metabolic syndrome patients
Disease control Recruiting nowThis study is testing a fixed-dose combination of two cholesterol-lowering drugs (Pitavastatin and Ezetimibe) in 10,000 adults with high cholesterol and metabolic syndrome. Researchers will track how much LDL ('bad') cholesterol drops after 24 and 48 weeks of treatment in real-wo…
Sponsor: JW Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo pill showdown: which diabetes cocktail wins?
Disease control Recruiting nowThis study tests four different drug combinations in 178 adults with type 2 diabetes whose blood sugar is not well controlled on metformin and an SGLT-2 inhibitor. Over 12 weeks, researchers will measure how much and how often blood sugar swings. The goal is to find which combo o…
Phase 4 • Sponsor: JW Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
One pill to tackle two heart risks: new combo drug enters final testing
Disease control Recruiting nowThis phase 3 trial is testing whether a new combination drug (JW0104+C2402) can safely lower both blood pressure and LDL cholesterol in people with hypertension and dyslipidemia. 162 participants will take the drug once daily for 8 weeks. The study is randomized and double-blind,…
Phase 3 • Sponsor: JW Pharmaceutical • Aim: Disease control
Last updated Jun 26, 2026 14:50 UTC
-
New drug aims to ease heavy periods caused by fibroids
Symptom relief Recruiting nowThis Phase 3 trial tests whether the experimental drug KLH-2109 can reduce heavy menstrual bleeding in people with uterine fibroids. About 254 participants will take either KLH-2109 or a standard treatment for 24 weeks, tracking their bleeding and visiting the clinic for safety c…
Phase 3 • Sponsor: JW Pharmaceutical • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
New skin cream tested on healthy people – no cure expected
Knowledge-focused Recruiting nowThis early-stage study tests whether a new topical cream called JW0061 is safe for healthy adults. About 104 Korean and Caucasian volunteers will apply the cream or a placebo. Researchers will check for skin irritation, changes in blood pressure, heart rate, and lab results. This…
Phase 1 • Sponsor: JW Pharmaceutical • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC